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Abstract
Infant formulas containing non-digestible oligosaccharides (NDO) similar to the composition
in breast milk or a combination of lactic acid bacteria (LAB) and NDO have been shown to
harbor preventive effects towards immune-regulatory disorders. The aim of this study was
to investigate the immune-modulatory potential of non-digestible short chain galacto- and
long chain fructo-oligosaccharides (scGOS/lcFOS) mimicking the natural distribution of oli-
gosaccharides in human breast milk in presence or absence of certain LAB strains in
human monocyte derived dendritic cells (MoDC). Immature human MoDC prepared from
peripheral blood of healthy non-atopic volunteers were screened in vitro after stimulation
with specific scGOS/lcFOS in presence or absence of LAB. IL-10 and IL-12p70 release was
analyzed after 24 hours in cell-free supernatants by enzyme-linked immunosorbent assay
(ELISA). A luminex-based assay was conducted to assess further cytokine and chemokine
release by MoDC. To investigate the resulting T cell response, stimulated MoDC were co-
incubated with naïve T cells in allogeneic stimulation assays and intracellular Foxp3 expres-
sion, as well as immune-suppressive capacity was determined. Oligosaccharides did not
induce relevant amounts of IL-12p70 production, but did promote IL-10 release by MoDC.
Furthermore, scGOS/lcFOSmixtures exerted a significant enhancing effect on LAB induced
IL-10 secretion by MoDC while no increase in IL-12p70 production was observed. Blocking
toll like receptor (TLR)4 abrogated the increase in IL-10 in both the direct stimulation and
the LAB stimulation of MoDC, suggesting that scGOS/lcFOS act via TLR4. Finally, scGOS/
lcFOS-treated MoDC were shown to upregulate the number of functional suppressive
Foxp3 positive T cells following allogeneic stimulation. Our results indicate anti-inflamma-
tory and direct, microbiota independent, immune-modulatory properties of scGOS/lcFOS
mixtures on human MoDC suggesting a possible induction of regulatory T cells (Tregs). The
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Introduction
Over the past decades predominantly western countries are facing an increasing occurrence of
chronic inflammatory diseases associated with loss of tolerance such as allergies or inflamma-
tory bowel disease. Accumulated evidence suggests a link between these immune-regulatory
disorders and an imbalance in the intestinal microbiota also referred to as dysbiosis [1–3]. An
adequate constitution of the intestinal microbiota and gut colonization in early stages of life is
crucial for maintaining health as adult [4]. It has been shown that the infant’s immune system
matures by exposure to the intestinal microbiota initiated by microbial colonization of the gut
through exposure to bacteria during birth and early life [5,6]. Evidence exists that breastfeeding
decreases the incidence of infections [7] and can be protective regarding allergic diseases [8,9].
Human milk plays an important role in the establishment of the microbiota and the matura-
tion of the child’s immune system [10] through its unique composition involving antimicrobial
properties, transfer of immunological and tolerogenic stimuli and its high content of non-
digestible human milk oligosaccharides (HMO) [11,12]. Infant formula supplemented with a
specific manufactured 9:1 mixture of short chain galacto-oligosaccharides and long chain
fructo-oligosaccharides (scGOS/lcFOS), resembling the composition of HMO is associated
with a reduced cumulative incidence of atopic dermatitis during the first six month of life. In a
follow-up study, a protective effect on the incidence of some allergic manifestations could be
observed after five years [13,14]. Moreover, a decreased occurrence of allergic manifestations at
the age of two and a reduced number of infectious episodes beyond the intervention period
have been reported in infants that received formula containing scGOS/lcFOS [15]. Addition-
ally, other studies showed a beneficial effect on mucosal immunity showing higher concentra-
tions of fecal secretory immunoglobulin (Ig)A [16,17], reduced levels of immunoglobulin free
light chain, and a beneficial immunoglobulin profile in infants at high risk for allergy [18,19].
Overall, these data suggest that infant formula supplemented with this specific mixture of
scGOS/lcFOS has immune-regulatory properties but much remains unknown about their
mechanism of action. Besides the known prebiotic effects of NDO on modulating the composi-
tion of the intestinal microbiota [20,21] possible direct systemic effects of NDO on epithelial
and immune cells are currently under investigation [22]. Naarding et al. showed that HMO
have the capacity to bind to the C-type lectin receptor dendritic cell-specific intercellular adhe-
sion molecule-3-grabbing non-integrin (DC-SIGN) on dendritic cells (DC) [23] and Capitan-
Canadas et al. recently described a non-prebiotic effect of oligosaccharides on monocytes via
activation of the pattern recognition receptor (PRR) Toll like receptor 4 (TLR4) in rats [24]. In
a follow-up study, a TLR4-mediated direct effect of NDO on human intestinal epithelial cell
lines could be demonstrated [25].
In this study, we analyzed the direct immune-modulatory effects of scGOS/lcFOS on
MoDC. We show that MoDC stimulation with scGOS/lcFOS increases IL-10 release in the
absence of IL-12 secretion. Furthermore, scGOS/lcFOS-treated MoDC were found to increase
the number of Foxp3+ T cells. Overall scGOS/lcFOS might contribute to intestinal homeostasis
via the induction of the anti-inflammatory cytokine IL-10 and the induction of Tregs.
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Methods
Subjects and Ethic Statement
For this study peripheral blood of healthy, non-atopic donors was used. Volunteers were
screened for total serum IgE levels and for specific IgE against common allergens as described
before [26] and non-atopic individuals were defined by total IgE lower 100 kU. The ethical
committee of Technische Universität München approved the study and all volunteers enrolled
in the study had given their written informed consent.
Bacteria Preparation
The Bifidobacterium breve strain NutRes200 as well as the Lactobacillus rhamnosus strain
NutRes1 were used. L.rhamnosus was available as 0.5 ml cultures of 5.9x109 cell counts stored
at -80°C. Lyophilized B.breve was diluted in D-PBS (Gibco/Invitrogen) and a 25x109 cfu/ml
stock solution was prepared and stored at -80°C. To prepare bacterial strains for stimulation
experiments, stocks were thawed, diluted appropriately in D-PBS (Gibco/Invitrogen) and con-
centrations of 1x105-1x107cfu/ml were generated by serial dilution in cell culture medium.
Generation of Monocyte Derived Dendritic Cells
For the generation of monocyte derived dendritic cells (MoDC) PBMC were isolated from
peripheral blood of healthy volunteers by density gradient centrifugation (Lymphoprep, Axis-
Shield). CD14+ monocytes were purified by MACS (CD14+ beads, Miltenyi Biotec) and cul-
tured in RPMI 1640 supplemented with 10% FBS (HyClone), 2 mmol/l L-glutamine, 20 mg/ml
gentamycin (all from Invitrogen Life Technologies) and 50 μmol/l 2-mercaptoethanol (Fluka)
at 37°C, 5% CO2 in the presence of 50 U/ml rhGM-CSF and 50 U/ml rhIL-4 (both Promocell).
Immature MoDC harvested on day 5 were>95% pure as analyzed by FACS analysis (CD14-
CD1a+ HLA-DR+ CD80low CD83- CD86low CD40low). MoDC were routinely checked for via-
bility (propidium iodide staining).
Stimulation of MoDC with scGOS/lcFOS and LAB
Immature MoDC were seeded into 96-well flat bottom plates (Nunc) at a density of 1x105
cells/ml in complete DC medium and treated with the bacterial strains at concentrations of
1x105-1x107cfu/ml. Bacterial stimulation was performed either in the absence or presence of
5mg/ml scGOS/lcFOS mixture (9:1; scGOS; Friesland Campina, lcFOS; Orafti). To block TLR4
activity, a TLR4 antagonist (5 μg/ml, LPS-RS Ultrapure, InvivoGen) was used. LPS (100 ng/ml,
Sigma) served as positive control for MoDC stimulation indicating functional MoDC stimula-
tion. Untreated MoDC were used as negative control. After 24 hours incubation at 37°C and
5% CO2, cytokines IL-10 (BD Biosciences) and IL-12p70 (eBioscience) were analyzed in cell-
culture supernatants by ELISA according to the manufacturer’s protocol. Furthermore, a
broader selection of MoDC released mediators were analyzed by a luminex-based assay con-
ducted by the Multiplex Core Facility Laboratory for Translational Immunology, Department
of Pediatric Immunology, University Medical Centre Utrecht. Expression of maturation mark-
ers CD80 (FITC-conjugated anti-human, BD), CD83 (PE-conjugated anti-human,
eBioscience), CD86 (APC-conjugated anti-human, BD), CD40 (FITC-conjugated anti-human,
eBioscience), HLA-DR (APC-conjugated anti-human, eBioscience) and viability were mea-
sured by flow cytometry after stimulation of MoDC.
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Allogeneic Stimulation Assay of Naïve T cells
The capacity of oligosaccharides-matured MoDC to instruct the polarization of T lymphocytes
was examined performing allogeneic stimulation assays (ASA). After 24 hours scGOS/lcFOS-
stimulated MoDC were washed and co-incubated with naïve CD4+CD45RA+ T cells at a DC:T
cell ratio of 1:10 in T cell medium containing RPMI supplemented with 1% L-glutamine,
1.12% nonessential amino acids, 1.12% sodium pyruvate, 1% pen-strep (all from Gibco), 1%
5 mMmercaptoethanol and human serum (5%, Lonza) for 7 days. Allogeneic CD4+CD45RA+
T cells were isolated from PBMC of non-atopic donors using the CD4+CD45RA+ naïve T Cell
Isolation Kit II (Miltenyi Biotech). A positive control for Treg polarization was generated by
priming naïve T cells with 5 ng/ml rhTGF-β (Promokine), 200 U/ml rhIL-2 (Novartis), 5 μg/
ml anti-IL-12 and 1 μg/ml aIFN-γ (both eBioscience) and co-culturing them with MoDC that
have been incubated with medium only. 20 U/ml rhIL-2 was added to the cells on the third day
of the ASA. After 7 days of co-culture cells were restimulated for 5 hours with phorbol
12-myristate 13-acetate/ionomycin (both Sigma Aldrich) in the presence of monensin
(eBioscience) and brefeldin A (BD Biosciences). Dead cells were excluded using the LIVE/
DEAD Fixable Aqua dead cell stain kit (Life Technologies) according to the manufacturer’s
instructions, followed by surface staining of CD4 (APC-Cy7-conjugated anti-human, BD Bio-
sciences). Cells were then fixed, permeabilized and stained for intracellular Foxp3 (APC-
conjugated anti-human, eBioscience) using a Foxp3 staining kit (eBioscience) and analyzed by
flow cytometry (FACSFortessa System, BD FACSDiva 7.0). The gating strategy of alive, CD4+,
Foxp3+ T cells is shown in S1 Fig.
Suppression Assay
To determine the functionality of potential regulatory effector T cells induced in the ASA,
these cells were harvested on day seven of the ASA and co-incubated with allogeneic freshly
isolated responder T cells (CD4+ T cell isolation Kit II, Miltenyi) at a ratio of 1:1 for five days in
96-well plates (BD) coated with anti-CD3 (1 μg/ml, BD). Soluble anti-CD28 (1 μg/ml, BD) and
rhIL-2 (100 U/ml) were added. Responder T cells were stained with Cell Trace Violet Cell Pro-
liferation Kit (Life Technologies) according to the manufacturers’ instructions at a final con-
centration of 6 μM and violet-positive cells were acquired on a FACS Fortessa (BD). The mix
of ASA cells and violet stained responder CD4+ T cells was then stained (after five days of co-
incubation) with CD4 APC-Cy7. Suppressive capacity was determined by setting gates on pro-
liferated and non-proliferated cells and analyzing the ratio of these cell populations. The gating
strategy of dividing/non-dividing CD4+ T cells is shown in S6 Fig.
Statistical Analysis
Data are presented as mean ± SEM and statistically analyzed using the Mann-Whitney-Test or
unpaired student’s t test, a p 0.05 was considered as statistically significant. Statistical analy-
sis was conducted using GraphPad Prism software (version 6.0).
Results
scGOS/lcFOS Induce IL-10 Secretion of MoDC in the Absence of IL-
12p70
To investigate whether scGOS/lcFOS can induce cytokine release by MoDC, immature human
MoDC were stimulated with scGOS/lcFOS (5 mg/ml). The incubation of MoDC with oligosac-
charides induced the release of IL-10 (Fig 1A), while no IL-12p70 release could be detected (Fig
1B). LPS-stimulated MoDC released both IL-10 and IL-12p70 (Fig 1A and 1B).
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MoDC were phenotypically analyzed after incubation with either medium, LPS or oligosac-
charides. Compared to medium, LPS induces maturation as measured by increased mean fluo-
rescence intensities (MFI) specific for maturation markers CD80, CD83 and CD86. In contrast
treatment with oligosaccharides only slightly upregulated maturation markers (S2 Fig). The
viability of MoDC was not affected by LPS- or scGOS/lcFOS-stimulation (S2 Fig).
scGOS/lcFOS Dose-dependently Activate TLR4
NDO were previously shown to stimulate TLR4 [25]. To investigate the potential involvement
of TLR4 in the MoDC cytokine release following scGOS/lcFOS stimulation, we conducted a
dose-response experiment in the presence and absence of a TLR4 antagonist. Stimulating
MoDC with scGOS/lcFOS in the presence of the TLR4 antagonist completely abrogated
MoDC IL-10 release (Fig 2, controls see S3 Fig).
Fig 1. MoDC primed with scGOS/lcFOS are characterized by release of IL-10 while no IL-12p70 secretion is detectable. Immature humanMoDC were
incubated with scGOS/lcFOS (5 mg/ml) for 24h. Medium-treated MoDC served as negative control, MoDCmatured by LPS as positive control for functional
MoDC stimulation. Supernatants were analyzed for secretion of IL-10 (A) and IL-12p70 (B) by ELISA. Results are presented as mean ± SEM, ten
independent experiments are shown. **** p<0.0001, ** p<0.01, unpaired student’s t test. scGOS/lcFOS = short chain galacto-, long chain fructo-
oligosaccharides, MoDC =monocyte-derived dendritic cells.
doi:10.1371/journal.pone.0132304.g001
Fig 2. Stimulation with scGOS/lcFOS directly induces a dose dependent IL-10 release by MoDC that is
impaired by addition of a TLR4 antagonist. Immature human MoDCwere exposed to oligosaccharide
mixture scGOS/lcFOS (312 μg/ml–5 mg/ml) for 24h in the presence (black marks) or absence (grey marks) of
a TLR4 antagonist. The amount of IL-10 was measured by ELISA in cell-free supernatant. Results are
presented as mean ± SEM, five independent experiments are shown. * p<0.05, MannWhitney test. scGOS/
lcFOS = short chain galacto-, long chain fructo-oligosaccharide-mixture, MoDC =monocyte-derived dendritic
cells.
doi:10.1371/journal.pone.0132304.g002
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The observation that, in contrast to LPS, scGOS/lcFOS stimulated MoDC released IL-10 in
the absence of IL-12 led us to consider whether other soluble mediators were also differentially
affected. Upon comparing the LPS- with the scGOS/lcFOS-induced MoDC profile of mediator
release several differences could be observed depending on the secreted mediator (Fig 3).
scGOS/lcFOS Enhance LAB-induced IL-10 Release
To examine how the presence of scGOS/lcFOS would affect LAB-induced MoDC cytokine
release, MoDC were stimulated with either B.breve or L.rhamnosus in the absence or presence
of scGOS/lcFOS. In contrast to L.rhamnosus, B.breve induced IL-10 release in the absence of
IL-12p70 (S4 Fig). Presence of scGOS/lcFOS significantly enhanced IL-10 release for both
strains while IL-12p70 release was not affected (Fig 4).
To investigate this differential effect on cytokine release in more detail, a larger selection of
MoDC-derived soluble mediators was analyzed. scGOS/lcFOS was found to enhance mediator
release depending both on the analyte measured and the bacterial strain used suggesting strain-
dependent effects (S5 Fig). To investigate the potential contribution of TLR4 activity to the
observed effect, MoDC were stimulated in the presence of a LPS antagonist. scGOS/lcFOS
dose-dependently increased B.breve-induced MoDC IL-10 release. Blocking of TLR4-activity
abrogated this enhanced effect (Fig 5).
Fig 3. scGOS/lcFOS-stimulated MoDC release cytokines and chemokines in a different manner compared to LPS.MoDCwere stimulated with
scGOS/lcFOS (5 mg/ml) for 24h. MoDCmatured by LPS served as positive control for functional stimulation. The amount of cytokines and chemokines in
cell-free supernatants was measured by luminex-based assay (readout: IL-1α, IL-1β, IL-6, IL-23p19, IL-27, TNFα, IP-10, MDC (CCL22), TARC (CCL17),
MIP3α (CCL20) and ELISA (IL-10, IL-12p70)). Results are presented in pg/ml. Three independent experiments are shown.
doi:10.1371/journal.pone.0132304.g003
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scGOS/lcFOS-Stimulated MoDC Induce Treg Development
DC release of IL-10 is associated with the induction of Tregs [27]. We therefore investigated
whether the IL-10 release following stimulation of MoDC with scGOS/lcFOS would lead to
induction of Tregs. MoDC were treated with scGOS/lcFOS for 24 hours, washed and subse-
quently co-cultured with naïve T cells in an allogeneic stimulation assay. Compared to control
MoDC (medium-treated MoDC control Fig 6A, positive Treg control Fig 6B), scGOS/lcFOS-
stimulated DC induced an upward shift in Foxp3 expressing T cells (Fig 6C). However, this
increase did not reach significance (Fig 6D).
These induced CD4+Foxp3+ T cells differentiated by scGOS/lcFOS-stimulated MoDC
showed in suppression assays an increased capacity to inhibit the proliferation of CD4+
responder cells (Fig 7A and 7E) compared to T cells induced by medium-/LPS-treated MoDC
and Treg control (Fig 7B–7D). As demonstrated in Fig 7F these scGOS/lcFOS-induced Foxp3+
Fig 4. LAB-primed MoDC stimulated with scGOS/lcFOS are characterized by an enhanced release of IL-10 while no enhanced IL-12p70 secretion is
detectable. Immature human MoDC were incubated with B.breve (clear dots, A, B) or L.rhamnosus (clear triangle, C, D) in different concentrations with
(black marks) or without (clear marks) scGOS/lcFOS (5 mg/ml) for 24h. Supernatants were analyzed for secretion of IL-10 (A, C) and IL-12p70 (B, D) by
ELISA. Results are presented as mean ± SEM, ten independent experiments are shown. * p<0.05, ** p<0.01, MannWhitney test. LAB = Lactic acid
bacteria, MoDC =monocyte-derived dendritic cells.
doi:10.1371/journal.pone.0132304.g004
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T cells are characterized by a low suppressive functionality index comparable to Treg control
which indicates a high capacity to inhibit the proliferation of CD4+ responder cells.
Discussion
It has been reported in animal trials and human clinical studies that NDO like scGOS/lcFOS
supplemented to infant formula can contribute to a decreased susceptibility to atopy and
allergy [16,28–30]. However, the exact mechanisms are still unclear but might involve the
direct effects of NDO on host-cells [31]. The specific mixture of scGOS/lcFOS, as used in this
study, was previously found to modulate cytokine release from CD3/CD28 stimulated PBMC
both directly and through effects on epithelial cells in 2D co-cultures [32], which suggest that
scGOS/lcFOS might stimulate (immune) cells directly. In this study, we evaluated whether
scGOS/lcFOS exert direct immune-modulatory effects on human MoDC. For the first time we
show direct, immune-modulatory effects of this unique combination of oligosaccharides on
human MoDC and the ensuing induced T cell response. We have shown that DC treated with
scGOS/lcFOS released IL-10 in the absence of IL-12p70 and that this effect is mediated via acti-
vation of TLR4. In contrast, TLR4 activation through LPS stimulation of MoDC released both
IL-10 and IL-12, which would argue against a potential bacterial product contamination of the
scGOS/lcFOS preparation. In line with this, upon measuring the endotoxin content of the
scGOS/lcFOS preparation using a LAL-assay, endotoxin content was measured to be very low
(<3 ng/ml). Moreover, upon analysis of additional soluble mediators (chemokines as well as
cytokines) the profile of scGOS/lcFOS induced release was markedly different from LPS, sug-
gesting that other PRR may play a role.
Several studies describe an immune modulation by different NDO on cellular level via the
interaction with specific sugar receptors including DC-SIGN, TLRs or C type lectin receptors
Fig 5. Stimulation with scGOS/lcFOS directly induces a dose dependent enhanced IL-10 release by
LAB-primed MoDC that is impaired by addition of a TLR4 antagonist. Immature humanMoDC were
exposed to oligosaccharide mixture scGOS/lcFOS (312 μg/ml–5 mg/ml) in the presence of B.breve at a
concentration of 1x106cfu/ml in the presence (black marks) or absence (grey marks) of a TLR4 antagonist.
The amount of IL-10 was measured by ELISA in cell-free supernatant after 24h. Results are presented as
mean ± SEM, five independent experiments are shown. * p<0.05, MannWhitney test. scGOS/lcFOS = short
chain galacto-, long chain fructo-oligosaccharide-mixture, MoDC =monocyte-derived dendritic cells,
TLR = Toll like receptor.
doi:10.1371/journal.pone.0132304.g005
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[24,25,33–35]. Further studies in our experimental setting are necessary to investigate the role
of other types of receptors involved in scGOS/lcFOS-mediated, direct mechanisms on human
MoDC. Synbiotics, which are a specific mixture of probiotic bacteria and prebiotic NDO, can
be ingredients of infant milk formulas [36]. Here the prebiotics are thought to act as substrates
for the probiotic bacteria thereby assisting in their probiotic function. Strains from Bifidobac-
teria and Lactobacilli are often considered as potential probiotic bacteria [37]. Here we evalu-
ated the contribution of the prebiotic mixture scGOS/lcFOS on the probiotic bacteria-induced
MoDC cytokine profile. MoDC strain-dependently released IL-10 and IL-12. This is in accor-
dance with previous data showing that different bacterial strains have different, strain-
dependent effects on cytokine release of human immune cells potentially through the differen-
tial use of PRR [38–41]. In line with the data observed on the direct effects of scGOS/lcFOS on
MoDC, the scGOS/lcFOS mixtures dose-dependently enhanced B.breve and L.rhamnosus
induced IL-10 release while IL-12 release was unaffected. Again, this effect could be blocked
using a LPS antagonist indicating a role for TLR4 in the observed effect. DC production of IL-
10 in the absence of IL-12p70 could contribute to the development of regulatory T cells [27,42–
44]. Additionally, treatment with oligosaccharides only slightly upregulated maturation
Fig 6. scGOS/lcFOS stimulated MoDC induce CD4+Foxp3+ T cells.MoDC stimulated with scGOS/lcFOS (5 mg/ml) were used to prime naïve
CD4+CD45RA+ T cells in an ASA. At day 7, cells were stained for CD4 and intracellular Foxp3 was analyzed by flow cytometry. The dot plots show data from
one representative experiment (A-C). T cells that have been co-incubated with medium-treated MoDC served as medium/negative control (A) and a positive
control for Treg polarization is shown in (B). CD4+Foxp3+ T cells induced by scGOS/lcFOS stimulated MoDC are shown in (C). Data in (D) are expressed as
percentages of CD4+Foxp3+ cells. Results are presented as mean ± SEM, 4 independent experiments are shown (D). * p<0.05, MannWhitney test.
ASA = allogeneic stimulation assay, scGOS/lcFOS = short chain galacto-, long chain fructo-oligosaccharides, MoDC =monocyte-derived dendritic cells.
doi:10.1371/journal.pone.0132304.g006
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markers CD80, CD83 and CD86 in comparison to LPS-matured DC. It has been postulated
that partially or semi-mature intestinal DC producing little IL-12 in the presence of IL-10 are
involved in induction of tolerance [27,45]. Experiments of this study show that treatment of
MoDC with scGOS/lcFOS led to an increase in Foxp3+ T cells, which is associated with an
increase in Treg [46,47]. Treg induction by scGOS/lcFOS shown in this study is in accordance
with previous studies where a diet containing scGOS/lcFOS increased vaccination responses in
mice but also decreased allergic symptoms in a mouse model of food-allergy [48,49]. According
to van der Aa et al. a combination of B.breve and scGOS/lcFOS induces Treg cell development
through modulation of DC function, preventing asthma-like symptoms in infants with atopic
dermatitis [50]. An intervention study in a mouse model for orally induced cow’s milk allergy
revealed a reduced acute allergic skin response and anaphylactic scores after dietary interven-
tion with scGOS/lcFOS in combination with B.breve. Also enhanced whey-specific Th1 type
serum IgG2a, fecal IgA and reduced mast cell degranulation was found in this study [51]. The
authors suggested a possible involvement of whey-specific CD25+ regulatory T cells in induc-
tion of tolerance by NDO and confirmed a role for regulatory T cells in suppressing casein
allergy by NDO [49,52]. An important role of regulatory T cells as well as anti-inflammatory
cytokine profiles in the prevention of allergies and related disorders has been affirmed by sev-
eral studies [53–55]. Finally, the results of our study provide support that the clinical efficacy of
scGOS/lcFOS displaying similar functionality as HMO supplemented to infant formula may
also relate in part to direct interaction with immune cells. Our data provides evidence for a
Fig 7. Suppressive capacity of T cells induced by scGOS/lcFOS-treated MoDC. T cells of allogeneic stimulation assays (ASA) were harvested on day
seven and co-incubated with freshly isolated, violet-labeled responder CD4+ T cells a ratio of 1:1 for five days in presence of anti-CD3/28 and rhIL-2. The mix
of ASA cells and violet stained responder CD4+ T cells was then stained (after five days of co-incubation) with CD4 APC-Cy7. The dot plots show data from
one representative experiment. Proliferation of responder T cells only (A) or in co-incubation with T cells induced by medium- (B), LPS- (C) and scGOS/
lcFOS- (E) stimulated MoDC and Treg control (D) is shown. Results in (F) are presented as mean ± SEM, 4 independent experiments are depicted.
Proliferation of violet-positive cells was analyzed by flow cytometry and suppressive functionality index was determined by calculating dividing cells (div)/
non-dividing (ndiv) cells (F). * p<0.05, MannWhitney test. ASA = allogeneic stimulation assay, scGOS/lcFOS = short chain galacto-, long chain fructo-
oligosaccharides, MoDC =monocyte-derived dendritic cells, div = dividing cells, ndiv = non-dividing cells.
doi:10.1371/journal.pone.0132304.g007
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direct immune-modulating effect on human dendritic cells involving TLR4 and subsequently
an induction of regulatory T cells that could lead to an attenuation or prevention of diseases
associated with loss of tolerance.
Supporting Information
S1 Fig. Gating strategy by means of FMO control.MoDC stimulated with scGOS/lcFOS
(5 mg/ml) were used to prime naïve CD4+CD45RA+ T cells in an ASA. At day 7, cells were
stained for CD4 but not intracellular Foxp3 analyzed by flow cytometry. The gating strategy
(with FMO control) is shown which was used to obtain percentages of CD4+Foxp3+ cells
shown in Fig 6. CD4+Foxp3+ cells were derived out the gate of alive cells after excluding dupli-
cates. scGOS/lcFOS = short chain galacto-, long chain fructo-oligosaccharides, ASA =-
allogeneic stimulation assay, FMO = fluorescence minus one, MoDC = monocyte-derived
dendritic cells.
(TIF)
S2 Fig. Oligosaccharides induce no full MoDC maturation compared to LPS.MoDC were
stimulated with oligosaccharides (5 mg/ml), LPS or medium for 24h. MoDC matured by LPS
served as positive control for functional stimulation. The mean fluorescence intensities (MFI)
specific for maturation markers CD80 (A), CD83 (B), CD86 (C), CD40 (D) and HLA-DR (E)
as well as cell viability (F; propidium iodide staining) were determined by flow cytometry.
Three to five independent experiments are shown.  p<0.05,  p<0.01, MannWhitney test.
(TIF)
S3 Fig. Effect of B.breve on MoDC cytokine release is not affected in the presence of a TLR4
antagonist. Immature human MoDC were incubated with B.breve (1x106cfu/ml) or LPS (100
ng/ml) in the presence or absence of a TLR4 antagonist (LPS-RS) for 24h. Medium- and TLR4
only-treated MoDC served as negative control, MoDCmatured by LPS as positive control for
functional MoDC stimulation. Results are presented as mean ± SEM, five independent experi-
ments are shown.  p<0.0001,  p<0.01, unpaired student’s t test.
(TIF)
S4 Fig. LAB B.breve and L.rhamnosus differ in their capacity to induce IL-12p70 secretion
by human MoDC while IL-10 release is induced in a comparable and dose dependent man-
ner. Immature human MoDC were stimulated with B.breve (dot) or L.rhamnosus (triangle) in
different concentrations (1x105-1x107cfu/ml) for 24h. Amounts of IL-10 (A) and IL-12p70 (B)
were measured by ELISA in cell-free supernatant. Results are presented as mean ± SEM, ten
independent experiments are shown.  p<0.05,  p<0.01,  p<0.001, Mann Whitney test.
LAB = Lactic acid bacteria, MoDC = monocyte-derived dendritic cells.
(TIFF)
S5 Fig. scGOS/lcFOS enhance cytokine and chemokine release by LAB-stimulated MoDC.
MoDC were stimulated with scGOS/lcFOS only or combinations of the mixture scGOS/lcFOS
(5 mg/ml) and either B.breve or L.rhamnosus at a concentration of 1x105 cfu/ml for 24h. The
amount of cytokines and chemokines in cell-free supernatants was measured by luminex-
based assay (readout: IL-1α, IL-1β, IL-6, IL-23p19, IL-27, TNFα, IP-10, MDC (CCL22), TARC
(CCL17), MIP3α (CCL20) and ELISA (IL-10, IL-12p70)). Results are presented as induction
factors that were obtained by dividing cytokine release of scGOS/lcFOS+LAB-stimulated
MoDC through cytokine secretion of MoDC incubated with scGOS/lcFOS only.
(TIFF)
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S6 Fig. Gating strategy by means of CD4+ responder only control. T cells of allogeneic stim-
ulation assays (ASA) were harvested on day seven and co-incubated with freshly isolated, vio-
let-labeled responder CD4+ T cells a ratio of 1:1 for five days in presence of anti-CD3/28 and
rhIL-2. The mix of ASA cells and violet stained responder CD4+ T cells was then stained (after
five days of co-incubation) with CD4 APC-Cy7. The gating strategy (obtained by CD4+
responder cells only) is demonstrated which was used to calculate the suppressive functionality
index shown in Fig 7. Dividing T cells (P4) and non-dividing T cells (P3) were derived out of
the CD4+ gate. ASA = allogeneic stimulation assay.
(TIF)
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